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Genetic alterations in the Wnt/b-catenin/TCF-signaling pathway are commonly found in human tumors, but
not in glioblastomas. In this issue of Cancer Cell, Zhang et al. report that FoxM1 mediates b-catenin nuclear
translocation in glioblastoma, suggesting a novel mechanism for glioblastoma progression in the absence of
conventional Wnt/b-catenin pathway activation.The role of the Wnt/b-catenin pathway in
normal development, including the con-
trol of stem cell self-renewal and prolifera-
tion, is well established (Clevers, 2006).
Not surprisingly,mutations in this pathway
result in aberrant activation of target
genes, such as MYC and CCND1, and
often lead to cancer (Clevers, 2006).
Pathway disruptions commonly include
mutations to adenomatous polyposis coli
(APC), a negative regulator of the path-
way, or tob-catenin itself, the fundamental
signaling effector. However, glioblastoma
multiforme (GBM), the most common and
aggressive glioma, rarely shows these
genetic abnormalities, though increased
b-catenin activation is present (Paraf
et al., 1997). Here, Zhang et al. (2011) des-
cribe a surprising mechanism for Wnt/
b-catenin signaling activation in GBM
and,more fundamentally, explain amech-
anism for b-catenin nuclear translocation
via binding to the transcription factor,
FoxM1.
FoxM1 is a forkhead box (Fox) tran-
scription factor with known roles in regu-
lating cell cycle progression by controlling
the G2/M transition, exit from the cell
cycle, and the stability of the mitotic
spindle. An expanding body of work has
linked FoxM1 upregulation to a variety of
cancers, including breast, gastric, and
lung cancer (Wang et al., 2010), marking
it as a proto-oncogene. Importantly, its
expression is often correlated with poor
prognosis (Wang et al., 2010). The fact
that FoxM1 interacts with numerous sig-
naling pathways and is associated with
many solid tumors makes it an attractive
molecular target for anticancer therapies.In the present study, Zhang et al. (2011)
probe the relationship between FoxM1
and b-catenin. Although it is known that
b-catenin nuclear translocation is impor-
tant for Wnt target gene regulation, the
mechanism by which this movement
happens has been surprisingly hard to
define. Notably, b-catenin lacks a nuclear
localization signal (NLS) and does not
depend on importins or Ran for nuclear
translocation (reviewed in Henderson
and Fagotto, 2002). Rather, Zhang et al.
(2011) demonstrate that FoxM1 is re-
quired for b-catenin nuclear translocation
because b-catenin fails to accumulate
in nuclei of FoxM1/ cells. The authors
further validate that translocation de-
pends on the binding of b-catenin to
FoxM1, which is mediated by armadillo
repeats 11–12 of b-catenin, and the Fox
domain of FoxM1. Moreover, this interac-
tion is maintained in nucleus, where both
proteins form a complex with TCF tran-
scription factors on the promoters of
Wnt/b-catenin target genes.
Zhang et al. (2011) go on to demon-
strate that the nuclear translocations of
both b-catenin and FoxM1 and their inter-
action drive the formation of gliomas.
Knockdown of either protein decreased
the self-renewal of glioblastoma-initiating
cells (GICs) in vitro and induced the ex-
pression of differentiation markers. These
results are consistent with a known role
for Wnt/b-catenin signaling in regulating
the cell cycle and cell fate choices of
mouse neural progenitor cells (Chenn
and Walsh, 2002), but whether FoxM1
plays a role in this nontumor context
is unknown. Additionally, reduction inCancer Cell 20FoxM1 in GICs resulted in a loss of tumor
formation in vivo. Interestingly, the tumor-
promoting ability of FoxM1 depended
completely on b-catenin because the ab-
sence of b-catenin abolished the potency
of FoxM1 to generate brain tumors.
Furthermore, the authors find that high
FoxM1 and nuclear b-catenin are corre-
lated in a panel of human GBMs, demon-
strating the relevance of these studies for
human disease. These results suggest
that targeting FoxM1, which is usually
absent from noncycling cells (Wang
et al., 2010), might effectively inhibit
glioma progression by excluding b-cate-
nin from the nucleus, and by extension,
blocking the activation of Wnt/b-catenin
target genes. In fact numerous small
molecules, including the antibiotic siomy-
cin A, have already been demonstrated
to reduce FoxM1 expression in various
tumor contexts (Wang et al., 2010).
The findings of Zhang et al. (2011) in
glioblastoma are interesting to compare
with medulloblastoma, a pediatric tumor
of the cerebellum. In agreement with the
current study, a recent report by Priller
et al. (2011) demonstrated that high
FoxM1 expression correlates with poor
prognosis in medulloblastoma. Addition-
ally, the molecular subgroup of medullo-
blastomawithWnt/b-catenin pathway ac-
tivation expresses high levels of FoxM1
protein (Priller et al., 2011). However, in
medulloblastoma high levels of nuclear
b-catenin are largely due to activating
mutations in the CTNNB1 gene itself
(Fattet et al., 2009), whereas b-catenin
mutations are usually absent from GBM.
Interestingly, unlike the current study, October 18, 2011 ª2011 Elsevier Inc. 415
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high nuclear b-catenin is an established
predictor of increased patient survival
(Ellison et al., 2005). How, then, does
a b-catenin/FoxM1 interaction function
in medulloblastoma, if it exists at all? Do
mutations to b-catenin at key regulatory
residues, which are common in medullo-
blastoma, alter the armadillo repeat-
mediated interaction of b-catenin with
FoxM1? It will be interesting to see what
a more thorough examination of the
FoxM1/b-catenin interaction in medullo-
blastoma can elucidate concerning this
discrepancy.
A further point that the current study
(Zhang et al., 2011) highlights is the
potential for a widespread interaction
between Fox proteins and the Wnt/
b-catenin signaling pathway. Previous
studies in C. elegans and mammalian
cells demonstrated a physical interaction
between b-catenin and multiple FOXO
proteins (Essers et al., 2005). Similar to
the results of Zhang et al. (2011), these
interactions were mediated by the arma-
dillo repeats of b-catenin and the portion
of the FOXO protein containing the fork-
head DNA-binding domain (Essers et al.,
2005). Additionally, there is precedence
for Wnt/b-catenin signaling in the regula-416 Cancer Cell 20, October 18, 2011 ª2011tion of Fox proteins. This is the case for
FoxN1, the protein that is mutated in
nude mice, resulting in athymic and hair-
less animals (Balciunaite et al., 2002). In
the thymus and the hair follicle, Wnt/
b-catenin pathway stimulation leads to
activation of FoxN1, which possesses
Wnt Response Elements (WREs) in its
promoter (Balciunaite et al., 2002). In
fact there may also be a reciprocal rela-
tionship between Wnt/b-catenin and
FoxM1 because FoxM1 can directly bind
to the promoter of human b-catenin and
regulate its expression in endothelial
cells. However, the frequency of cross-
regulation between these two pathways,
in both normal and tumor environments,
remains to be seen. Additionally, whether
FoxM1 can regulate b-catenin nuclear
translocation in other cell contexts has
yet to be established. In any case this
study illuminates the potential for Wnt/
b-catenin pathway control by an unusual
source, FoxM1, and the role for these
proteins in glioblastoma progression.
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Oncolytic viruses exploit molecular differences between normal and cancer cells to selectively kill the latter.
Results of a synthetic lethal screen described in this issue of Cancer Cell demonstrate that components of
the unfolded protein response (UPR) limit virus-induced tumor cell killing and identify a strategy to utilize
this knowledge.Productive viral infection mimics onco-
genic transformation in several respects,
and some of the same molecular mecha-
nisms are employed by viruses and
cancer cells to disrupt key homeostatic
mechanisms. These similarities serve asthe foundation for the development of
‘‘oncolytic’’ viruses that are designed
to specifically target and kill cancer
cells (Parato et al., 2005). Although
some targeting strategies involve engi-
neering viruses so that they bind specifi-cally to cancers, an even more attrac-
tive approach involves developing
viruses that can only replicate in cancer
cells that contain specific defects in
homeostatic control. For example one
of the products of the adenovirus E1B
